Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone301-366-4841
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$260,000.00
Profitability
Miscellaneous
Employees6
OptionableOptionable
Neuralstem (NASDAQ:CUR) Frequently Asked Questions
What is Neuralstem's stock symbol?
Neuralstem trades on the NASDAQ under the ticker symbol "CUR."
How were Neuralstem's earnings last quarter?
Neuralstem, Inc. (NASDAQ:CUR) announced its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.12) earnings per share for the quarter. Neuralstem had a negative net margin of 1,783.78% and a negative return on equity of 123.22%. View Neuralstem's Earnings History.
When is Neuralstem's next earnings date?
Has Neuralstem been receiving favorable news coverage?
News stories about CUR stock have trended neutral on Sunday, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neuralstem earned a media sentiment score of 0.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Are investors shorting Neuralstem?
Neuralstem saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 331,012 shares, a decrease of 43.1% from the December 14th total of 581,431 shares. Based on an average trading volume of 144,511 shares, the short-interest ratio is presently 2.3 days. Currently, 1.8% of the shares of the company are sold short. View Neuralstem's Current Options Chain.
Who are some of Neuralstem's key competitors?
Some companies that are related to Neuralstem include TRACON Pharmaceuticals (TCON), Microbot Medical (MBOT), CytRx (CYTR), Vical (VICL), Titan Pharmaceuticals (TTNP), aTyr Pharma (LIFE), Windtree Therapeutics (WINT), Mymetics (MYMX), Aevi Genomic Medicine (GNMX), Vaxart (VXRT), TrovaGene (TROV), Genetic Technologies (GENE), Enzon Pharmaceuticals (ENZN), Mateon Therapeutics (MATN) and Vitro Diagnostics (VODG).
Who are Neuralstem's key executives?
Neuralstem's management team includes the folowing people:
- Dr. Kenneth C. Carter, CEO & Exec. Chairman (Age 59)
- Dr. Karl Y. Johe Ph.D., Co-Founder & Chief Scientific Officer (Age 59)
- Dr. Thomas G. Hazel Ph.D., Sr. VP of Research
- Dr. David P. Recker, Chief Medical Officer (Age 61)
How do I buy shares of Neuralstem?
Shares of CUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neuralstem's stock price today?
One share of CUR stock can currently be purchased for approximately $0.4080.
How big of a company is Neuralstem?
Neuralstem has a market capitalization of $7.43 million and generates $260,000.00 in revenue each year. Neuralstem employs 6 workers across the globe.
What is Neuralstem's official website?
How can I contact Neuralstem?
Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected]
MarketBeat Community Rating for Neuralstem (NASDAQ CUR)
MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe CUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
